An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection

Journal of Virology

Volumn 89, Issue 8, 2015, Pages 4549-4561

  Zanin, Mark ^a   Keck, Zhen Yong ^b   Jonah Rainey, G ^c,d   Lam, Chia Ying Kao ^c   Boon, Adrianus C M ^a,e   Rubrum, Adam ^a   Darnell, Daniel ^a   Wong, Sook San ^a   Griffin, Yolanda ^a   Xia, Jinming ^b   Webster, Robert G ^a   Webby, Richard ^a   Johnson, Syd ^c   Foung, Steven ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Analytical Sciences   (United States)

^d MEDIMMUNE   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC FC FUSION PROTEIN; EPITOPE; FCDART ANTIBODY; HYBRID PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FERRET; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A (H5N1); MALE; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS MUTANT; VIRUS STRAIN; ANIMAL; CHO CELL LINE; CRICETULUS; DOG; FLUORESCENT ANTIBODY TECHNIQUE; HAMSTER; HEK293 CELL LINE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); MDCK CELL LINE; ORTHOMYXOVIRIDAE INFECTIONS; SERODIAGNOSIS;

AVIAN INFLUENZA VIRUS; MUS; MUSTELA; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; FERRETS; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; MICE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84925454498     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00078-15     Document Type: Article

References (39)

1. Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y. 2010. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 20:51-61. http://dx.doi.org/10.1038/cr.2009.124.
2. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, Sorrell EM, Bestebroer TM, Burke DF, Smith DJ, Rimmelzwaan GF, Osterhaus AD, Fouchier RA. 2012. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336:1534-1541. http://dx.doi.org/10.1126/science.1213362.
3. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katsura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428. http://dx.doi.org/10.1038/nature10831.
4. Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K. 2004. The evolution of H5N1 influenza viruses in ducks in southern China. Proc Natl Acad Sci U S A 101:10452-10457. http://dx.doi.org/10.1073/pnas.0403212101.
5. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E. 2005. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79:2191-2198. http://dx.doi.org/10.1128/JVI.79.4.2191-2198.2005.
6. World Health Organization Global Influenza Program Surveillance Network. 2005. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 11:1515-1521. http://dx.doi.org/10.3201/eid1110.050644.
7. Keating GM, Plosker GL, Lyseng-Williamson KA. 2012. A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use. BioDrugs 26:425-430. http://dx.doi.org/10.2165/11209740-000000000-00000.
8. Yen HL, Monto AS, Webster RG, Govorkova EA. 2005. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192:665-672. http://dx.doi.org/10.1086/432008.
9. Chen Y, Luo W, Wu WL, Fang Z, Xia L, Gui X, Chen H, Shih JW, Xia N. 2010. Humanized antibodies with broad-spectrum neutralization to avian influenza virus H5N1. Antiviral Res 87:81-84. http://dx.doi.org/10.1016/j.antiviral.2010.04.012.
10. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 199:49-58. http://dx.doi.org/10.1086/594374.
11. Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. 2006. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7:126. http://dx.doi.org/10.1186/1465-9921-7-126.
12. Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P. 2012. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 86:2978-2989. http://dx.doi.org/10.1128/JVI.06665-11.
13. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha DQ, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4:e178. http://dx.doi.org/10.1371/journal.pmed.0040178.
14. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA. 2012. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:526-532. http://dx.doi.org/10.1038/nature11414.
15. Kashyap AK, Steel J, Rubrum A, Estelles A, Briante R, Ilyushina NA, Xu L, Swale RE, Faynboym AM, Foreman PK, Horowitz M, Horowitz L, Webby R, Palese P, Lerner RA, Bhatt RR. 2010. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivorbased libraries. PLoS Pathog 6:e1000990. http://dx.doi.org/10.1371/journal.ppat.1000990.
16. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le M, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa M, Kawaoka Y. 2010. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88:249-255. http://dx.doi.org/10.1016/j.antiviral.2010.09.007.
17. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273. http://dx.doi.org/10.1038/nsmb.1566.
18. + memory B cells. PLoS One 3:e3942. http://dx.doi.org/10.1371/journal.pone.0003942.
19. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5:e1000350. http://dx.doi.org/10.1371/journal.ppat.1000350.
20. Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J. 2010. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 5:e9106. http://dx.doi.org/10.1371/journal.pone.0009106.
21. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856. http://dx.doi.org/10.1126/science.1205669.
22. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251. http://dx.doi.org/10.1126/science.1171491.
23. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737. http://dx.doi.org/10.1016/S0264-410X(00)00395-9.
24. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343-1351. http://dx.doi.org/10.1056/NEJMoa055778.
25. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407-10416. http://dx.doi.org/10.1128/JVI.74.22.10407-10416.2000.
26. Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, Lai MM, Foung SK. 2004. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 78:7257-7263. http://dx.doi.org/10.1128/JVI.78.13.7257-7263.2004.
27. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427. http://dx.doi.org/10.1016/0092-8674(82)90135-0.
28. Yewdell JW, Webster RG, Gerhard WU. 1979. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279:246-248. http://dx.doi.org/10.1038/279246a0.
29. Yamada S, Suzuki Y, Suzuki T, Le MQ, Nidom CA, Sakai-Tagawa Y, Muramoto Y, Ito M, Kiso M, Horimoto T, Shinya K, Sawada T, Usui T, Murata T, Lin Y, Hay A, Haire LF, Stevens DJ, Russell RJ, Gamblin SJ, Skehel JJ, Kawaoka Y. 2006. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444:378-382. http://dx.doi.org/10.1038/nature05264.
30. Longini IM, Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME. 2005. Containing pandemic influenza at the source. Science 309:1083-1087. http://dx.doi.org/10.1126/science.1115717.
31. Berry JD, Gaudet RG. 2011. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology.NBiotechnol 28:489-501. http://dx.doi.org/10.1016/j.nbt.2011.03.018.
32. Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183-186. http://dx.doi.org/10.1126/science.1225416.
33. Yamada T. 2011. Therapeutic monoclonal antibodies. Keio J Med 60:37-46. http://dx.doi.org/10.2302/kjm.60.37.
34. Han T, Marasco WA. 2011. Structural basis of influenza virus neutralization. Ann N Y Acad Sci 1217:178-190. http://dx.doi.org/10.1111/j.1749-6632.2010.05829.x.
35. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435-10446. http://dx.doi.org/10.1128/JVI.01715-13.
36. Brandenburg B, Koudstaal W, Goudsmit J, Klaren V, Tang C, Bujny MV, Korse HJ, Kwaks T, Otterstrom JJ, Juraszek J, van Oijen AM, Vogels R, Friesen RH. 2013. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One 8:e80034. http://dx.doi.org/10.1371/journal.pone.0080034.
37. Feng JQ, Mozdzanowska K, Gerhard W. 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutininspecific antibodies depending on their fine antigen specificity and heavychain isotype. J Virol 76:1369-1378. http://dx.doi.org/10.1128/JVI.76.3.1369-1378.2002.
38. Mozdzanowska K, Feng J, Eid M, Zharikova D, Gerhard W. 2006. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 352:418-426. http://dx.doi.org/10.1016/j.virol.2006.05.008.
39. Bumbaca D, Wong A, Drake E, Reyes AE, II, Lin BC, Stephan JP, Desnoyers L, Shen BQ, Dennis MS. 2011. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 3:376-386. http://dx.doi.org/10.4161/mabs.3.4.15786.